Which Stages Shape When a PGT Report Becomes Available?

A PGT report does not appear at a single moment. It is the end point of a chain that begins on the day an embryo is biopsied and passes through sample handling, laboratory analysis and clinical review before anyone can read a result. If you are trying to plan around a report date, it helps to know where the time actually goes, which parts are controlled by the genetics laboratory, and which parts depend on your clinic’s own schedule.

This guide explains the stages in order. It does not give turnaround times, because those depend on the specific laboratory, the test type and the workload at the time. Instead, it shows you what to ask so that an expected date is based on your own case rather than a general impression.

Stage 1: Embryo culture and the day of biopsy

The clock starts when a sample is taken, not when the cycle begins. In a typical PGT cycle, embryos are cultured for several days and a small number of cells is removed from the trophectoderm, the outer layer that will form the placenta, at the blastocyst stage. The embryo biopsy process and timing matter here for a simple reason: an embryo biopsied on day five and one biopsied on day six do not enter the laboratory queue on the same date.

This stage is largely clinic-controlled. It depends on how the embryos develop, which day the embryology team judges biopsy appropriate, and the laboratory’s own working days. If a cycle produces embryos that reach blastocyst on different days, samples may reach the genetics laboratory in more than one batch. That is one reason a single “report date” can be harder to pin down than patients expect.

It is worth knowing how your clinic labels blastocysts, because the day number in a report often traces back to this stage. The guide to day-five, day-six and day-seven blastocyst labels explains what those numbers mean.

Stage 2: Sample handling, labelling and transport

Once cells are removed, they become a specimen that must be identified, prepared and moved to the genetics laboratory. Sample processing at this point is about custody and traceability as much as biology: correct labelling, the right container, and a documented handover. If the genetics laboratory is on the same site as the IVF laboratory, transport is short. If it is elsewhere, the sample has to travel under agreed conditions.

This is a stage where small administrative problems can add delay. A mislabelled tube, an incomplete request form or a missing clinical detail may need to be resolved before analysis can begin. You will not see this happen, but it is one reason a clinic may ask for information about your history before the laboratory starts work.

Stage 3: DNA amplification and library preparation

The biopsy sample contains very little DNA, so the laboratory must amplify it before analysis. This preparation step is technical and largely invisible to patients, but it is a genuine part of the timeline. The sample has to be processed to a point where the chosen testing method can read it reliably.

For PGT-A, which assesses chromosome number, the laboratory prepares the sample for a genome-wide analysis. For PGT-M, which looks at a known monogenic condition, and PGT-SR, which looks at chromosomal structural rearrangements, the test is designed around a specific family situation. The HFEA’s information on PGT-M and PGT-SR explains that these tests address different questions and require discussion of the relevant history and test design with a treating team and genetic counsellor.

That test design is the main reason PGT-M often takes longer than PGT-A. A PGT-M test may need to be built and validated around your family’s specific genetic variant, sometimes using samples from relatives, before an embryo sample can be interpreted. This preparatory work can happen before or alongside an IVF cycle, but it is a separate task from analysing the biopsy itself. PGT-SR also involves test-specific design, though the details vary by rearrangement.

Stage 4: Sequencing or other analysis

With the sample prepared, the laboratory runs its analysis. Different methods suit different questions: PGT-A is commonly analysed with next-generation sequencing, while PGT-M may use PCR-based or sequencing approaches depending on the design. The method affects how the data are generated and how much interpretation is needed afterwards, but the laboratory, not the patient, decides which is appropriate.

This is the stage most people picture when they think about laboratory turnaround. It is also the stage where batching matters. Laboratories often run samples in groups rather than one at a time, so the date your sample enters the run can matter as much as the length of the run itself.

Stage 5: Bioinformatics analysis and quality review

Raw data are not a report. The laboratory has to analyse the output, check that the sample met quality thresholds, and decide whether the result is clear enough to report. Some samples need repeat analysis or are reported with caveats. The HFEA’s PGT-A information notes that testing has limitations and can produce incorrect findings, which is part of why this review step exists.

Quality review is also where nuanced findings are handled. A mosaic PGT-A result, for example, is inferred from intermediate chromosome copy-number findings in a biopsy sample, and technical factors can contribute to such findings. The ASRM committee opinion on mosaic PGT-A results makes clear that a sampled result does not establish the cell composition of the whole embryo. Reports that include this kind of finding may take longer to finalise because the wording and interpretation need care. The guide to understanding PGT-A results and mosaicism covers how to read such reports.

Stage 6: Clinical scientist sign-off and report release

Before a report reaches you, it is reviewed and signed off by the laboratory’s clinical team. This is a professional checkpoint, not a formality. The report then has to be released to your clinic through whatever channel has been agreed.

This stage is where clinic and laboratory responsibilities meet. The laboratory controls the analysis and sign-off; your clinic controls how and when the result is communicated to you. A report may be finalised on a date when your treating clinician is not immediately available to discuss it, and some clinics prefer to schedule a conversation rather than send a result without context.

Stage 7: How the result reaches you

Ask in advance how results will be shared: a portal, a scheduled call, an email with a follow-up appointment, or a conversation at your next visit. Ask who will explain the report and whether a genetic counsellor is involved. For PGT-M and PGT-SR, discussion with a genetic counsellor is part of interpreting what the result does and does not mean.

If you are planning to travel home after the cycle, this stage deserves early attention. A result that arrives after you leave may need a remote conversation, and any records you want for your home clinic should be requested explicitly. The guide to checking for missing records before an IVF clinic handover is a useful prompt for that conversation.

Which stages are laboratory-controlled and which are clinic-controlled

Stage	Mainly controlled by	What you can reasonably ask about
Embryo culture and biopsy day	IVF clinic and embryology team	Which day biopsy is planned and whether samples are batched
Sample handling and transport	IVF laboratory and genetics laboratory	Where the genetics laboratory is and how samples are transferred
Amplification and test design	Genetics laboratory	Whether test design is already complete for PGT-M or PGT-SR
Analysis run	Genetics laboratory	How often runs are scheduled
Bioinformatics and quality review	Genetics laboratory	What happens if a sample needs repeat analysis
Sign-off and release	Genetics laboratory, then your clinic	Who releases the report and to whom
Communication to you	Your clinic	Format, timing and who will explain the result

How to get a realistic expected date

Rather than asking “how long does PGT take?”, ask for a date range tied to your own cycle and test type. A useful request sounds like this: “For our situation, with biopsy planned around this date and this test type, what is the expected window for a signed report, and what could move it?” Then ask for a named point of contact for follow-up and the clinic’s process if the window passes without a result.

It also helps to separate the two clocks. The laboratory clock starts when a suitable sample arrives. The clinic clock includes scheduling, communication and any conversation needed to explain the result. A report can be ready while the discussion is still being arranged, and that gap is worth planning for, especially if you have travel dates.

Finally, keep a simple record of dates: biopsy day, the date you were told the sample was sent, the expected window, and any follow-up you have requested. If you are comparing clinics or preparing questions, the PGT laboratory quality questions for Thai IVF clinics can help you frame them. A coordinator can help organise these questions and request documents, but the clinical interpretation of your report belongs with your treating clinician and, where relevant, a genetic counsellor.

Frequently asked questions

Does a day-six biopsy always mean a later report than a day-five biopsy?

Not necessarily, but it can shift the start date. A sample taken later enters the laboratory queue later, and if samples are batched, the difference may be absorbed or may add time. Ask your clinic how it handles samples from different biopsy days.

Why might a PGT-M report take longer than a PGT-A report?

PGT-M is designed around a specific monogenic condition and may require test development and validation before an embryo sample can be interpreted. PGT-A assesses chromosome number across the genome and does not usually need that family-specific design step. The exact difference depends on the laboratory and whether test design is already complete.